Hypothermic Machine Perfusion for Liver Graft Preservation (HOPE-Liver)
Prospective and Randomized Clinical Study of the Effect of Hypothermic Machine Perfusion on Liver Graft Preservation
The goal of this clinical trial is to evaluate whether hypothermic machine perfusion improves liver graft preservation and post-transplant outcomes compared to conventional static cold storage in adult patients undergoing liver transplantation. This study focuses on liver grafts from deceased donors, including those with extended criteria, which are more susceptible to ischemia-reperfusion injury and early graft dysfunction.
The main questions it aims to answer are:
Does hypothermic machine perfusion reduce ischemia-reperfusion injury and improve early graft function after liver transplantation? Does this preservation strategy improve clinical outcomes, including graft survival, complication rates, and post-transplant recovery, compared to static cold storage?
Researchers will compare hypothermic machine perfusion (ex situ, oxygenated perfusion at low temperature) to standard static cold storage to assess differences in graft preservation quality and post-transplant outcomes.
Participants will:
Receive a liver graft preserved either by hypothermic machine perfusion or static cold storage, according to a 1:1 randomization protocol Undergo standard liver transplantation procedures Be followed after transplantation with clinical, laboratory, imaging, and biomarker assessments at predefined time points (7 days, 30 days, 6 months, and 1 year)
Additional evaluations will include biochemical markers of liver function, inflammatory and immunological mediators, mitochondrial function assessment, and histological analysis to better characterize graft injury and recovery.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a prospective, single-center, randomized controlled clinical trial designed to evaluate the impact of hypothermic machine perfusion on liver graft preservation and post-transplant outcomes in adult liver transplantation.
Liver transplantation is the standard treatment for end-stage liver disease; however, outcomes are strongly influenced by graft quality. The increasing use of extended criteria donors has introduced additional challenges, as these grafts are more susceptible to ischemia-reperfusion injury, a key determinant of early graft dysfunction and post-transplant complications. Conventional static cold storage, although widely used, does not prevent ongoing anaerobic metabolism and progressive depletion of cellular energy stores, contributing to mitochondrial dysfunction, oxidative stress, and inflammatory activation upon reperfusion.
Hypothermic machine perfusion has emerged as an alternative preservation strategy by providing continuous oxygenated perfusion under controlled hypothermic conditions. This approach aims to preserve mitochondrial integrity, reduce metabolic stress, and mitigate ischemia-reperfusion injury, thereby potentially improving graft viability and expanding the utilization of marginal organs.
In this study, liver grafts from deceased donors will be allocated to either hypothermic machine perfusion or conventional static cold storage. Following procurement, grafts assigned to the intervention group will undergo ex situ hypothermic perfusion using an oxygenated preservation solution under controlled conditions, while the control group will follow standard institutional preservation protocols.
All transplant procedures and perioperative management will be conducted according to institutional standards. Post-transplant follow-up will include clinical and laboratory monitoring to assess graft function and detect complications.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Wellington Andraus, MD, PhD
- Telefoonnummer: +5511982118909
- E-mail: wellington@usp.br
Studie Contact Back-up
- Naam: Alexandre Santana, PhD
- Telefoonnummer: +5511931002779
- E-mail: alesantana@usp.br
Studie Locaties
-
-
São Paulo
-
São Paulo, São Paulo, Brazilië, 05403-000
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
-
Contact:
- Wellington Andraus, MD, PhD
- Telefoonnummer: +5511982118909
- E-mail: wellington@usp.br
-
Contact:
- Alexandre Santana, PhD
- Telefoonnummer: +5511931002779
- E-mail: alesantana@usp.br
-
Hoofdonderzoeker:
- Wellington Andraus, MD, PhD
-
Onderonderzoeker:
- Rubens Junior, MD, PhD
-
Onderonderzoeker:
- Alexandre Santana, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Donor-related inclusion criteria:
- Liver donors with confirmed diagnosis of brain death.
- Extended criteria donors (ECD).
- Age ≥18 years.
- Family consent for organ donation obtained.
- Negative serology for HTLV, HIV, Chagas disease, and hepatitis B and C.
Recipient-related inclusion criteria:
- Adult patients (≥18 years) undergoing liver transplantation.
- Diagnosis of end-stage liver disease or indication for liver transplantation.
- Candidates for primary liver transplantation.
- Ability to understand and provide written informed consen
Donor-related exclusion criteria:
- Presence of moderate or severe hepatic steatosis.
- Pediatric donors.
- Donors classified as ideal, defined by the simultaneous presence of all of the following criteria: Age <35 years, Body mass index (BMI) <28 kg/m², No history of cardiopulmonary resuscitation, Norepinephrine requirement <0.5 µg/kg/min, Liver enzymes (AST or ALT) ≥2 times the upper limit of normal, Intensive care unit stay ≤7 days
Recipient-related exclusion criteria:
- Complex portal vein thrombosis (grade III or IV).
- Combined or dual organ transplantation.
- Retransplantation.
- Acute liver failure.
- MELD score >30.
- History of multiple prior liver or biliary surgeries.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Hypothermic Machine Perfusion
Liver grafts are preserved using hypothermic machine perfusion prior to transplantation.
Following procurement and an initial period of static cold storage, grafts undergo ex situ hypothermic oxygenated perfusion under controlled conditions before implantation.
|
Hypothermic machine perfusion of the liver graft is performed prior to transplantation using an ex situ perfusion system under controlled conditions, in which an oxygenated perfusate is circulated through the liver graft vasculature.
|
|
Actieve vergelijker: Static Cold Storage
Liver grafts are preserved using conventional static cold storage according to standard institutional protocols.
Following procurement, grafts are maintained under hypothermic conditions without active perfusion or oxygenation until implantation.
|
Liver graft preservation using conventional static cold storage under hypothermic conditions until transplantation.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of Early Allograft Dysfunction (EAD)
Tijdsspanne: Within 7 days after transplantation
|
Early allograft dysfunction is defined according to established clinical criteria, including at least one of the following within the first 7 days after transplantation: total bilirubin ≥10 mg/dL on day 7, international normalized ratio (INR) ≥1.6 on day 7, or alanine or aspartate aminotransferase (ALT or AST) levels >2000 IU/L within the first 7 days.
|
Within 7 days after transplantation
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Liver Function Tests (AST, ALT, Total Bilirubin)
Tijdsspanne: At 7 days, 30 days, 6 months, and 1 year after transplantation
|
Serial measurements of liver function parameters, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin, obtained through routine laboratory testing following liver transplantation.
Values will be analyzed over time to assess graft function and recovery.
|
At 7 days, 30 days, 6 months, and 1 year after transplantation
|
|
Incidence of Acute Kidney Injury (AKI)
Tijdsspanne: Within 7 days and up to 30 days after transplantation
|
Occurrence of acute kidney injury following liver transplantation, defined based on changes in serum creatinine levels according to established clinical criteria.
|
Within 7 days and up to 30 days after transplantation
|
|
Incidence of Post-Reperfusion Syndrome (PRS)
Tijdsspanne: During transplantation procedure
|
Occurrence of post-reperfusion syndrome during liver transplantation, defined as a decrease in mean arterial pressure greater than 30% from baseline within the first minutes after graft reperfusion, with or without the need for increased vasopressor support.
|
During transplantation procedure
|
|
Incidence of Post-Transplant Complications
Tijdsspanne: Up to 1 year after transplantation
|
Occurrence of post-transplant complications, including biliary complications, vascular complications, infections, and acute rejection, assessed according to standard clinical definitions and severity grading systems.
|
Up to 1 year after transplantation
|
|
Graft Survival
Tijdsspanne: Up to 1 year after transplantation
|
Survival of the transplanted liver graft without the need for retransplantation
|
Up to 1 year after transplantation
|
|
Patient Survival
Tijdsspanne: Up to 1 year after transplantation
|
Survival of the transplant recipient following liver transplantation.
|
Up to 1 year after transplantation
|
|
Length of Intensive Care Unit Stay
Tijdsspanne: From liver transplantation until intensive care unit discharge, up to 30 days
|
Duration of stay in the intensive care unit following liver transplantation.
|
From liver transplantation until intensive care unit discharge, up to 30 days
|
|
Length of Hospital Stay
Tijdsspanne: From liver transplantation until hospital discharge, up to 30 days
|
Duration of hospital stay following liver transplantation.
|
From liver transplantation until hospital discharge, up to 30 days
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Analysis of Perfusate Biomarkers
Tijdsspanne: During machine perfusion and immediately prior to transplantation
|
Assessment of biochemical and metabolic biomarkers in perfusate samples collected during hypothermic machine perfusion, aiming to evaluate graft viability and ischemia-reperfusion injury.
|
During machine perfusion and immediately prior to transplantation
|
|
Assessment of Mitochondrial Function Biomarkers (Flavin Mononucleotide, FMN)
Tijdsspanne: During machine perfusion period
|
Measurement of mitochondrial injury and function through biomarkers such as flavin mononucleotide (FMN) in perfusate and/or biological samples, as an indicator of ischemia-reperfusion injury and graft viability.
|
During machine perfusion period
|
|
Assessment of Inflammatory Biomarkers
Tijdsspanne: During machine perfusion and within the first 7 days after transplantation
|
Evaluation of inflammatory mediators, including cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), in biological samples to characterize the inflammatory response associated with transplantation and preservation strategies.
|
During machine perfusion and within the first 7 days after transplantation
|
|
Histological Assessment of Liver Graft Injury
Tijdsspanne: During the perioperative period, including before and after machine perfusion and prior to transplantation
|
Histological evaluation of liver tissue samples to assess ischemia-reperfusion injury, inflammation, and structural integrity of the graft.
|
During the perioperative period, including before and after machine perfusion and prior to transplantation
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Wellington Andraus, MD, PhD, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
- Studie stoel: Rubens Macedo Junior, MD, PhD, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
- Studie directeur: Alexandre Santana, PhD, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
Publicaties en nuttige links
Algemene publicaties
- Czigany Z, Lurje I, Schmelzle M, Schoning W, Ollinger R, Raschzok N, Sauer IM, Tacke F, Strnad P, Trautwein C, Neumann UP, Fronek J, Mehrabi A, Pratschke J, Schlegel A, Lurje G. Ischemia-Reperfusion Injury in Marginal Liver Grafts and the Role of Hypothermic Machine Perfusion: Molecular Mechanisms and Clinical Implications. J Clin Med. 2020 Mar 20;9(3):846. doi: 10.3390/jcm9030846.
- Patrono D, Surra A, Catalano G, Rizza G, Berchialla P, Martini S, Tandoi F, Lupo F, Mirabella S, Stratta C, Salizzoni M, Romagnoli R. Hypothermic Oxygenated Machine Perfusion of Liver Grafts from Brain-Dead Donors. Sci Rep. 2019 Jun 27;9(1):9337. doi: 10.1038/s41598-019-45843-3.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 7.497.991
- 2025/08106-0 (Ander subsidie-/financieringsnummer: São Paulo Research Foundation (FAPESP))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .